{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T21:46:38Z","timestamp":1782510398562,"version":"3.54.5"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ucl.2026.03.005","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T11:17:23Z","timestamp":1777288643000},"page":"393-412","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Emerging Intravesical Therapies for Non\u2013Muscle-Invasive Bladder Cancer"],"prefix":"10.1016","volume":"53","author":[{"given":"Betty","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaha","family":"Isali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Calaway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bukavina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ucl.2026.03.005_bib1","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.juro.2016.12.090","article-title":"Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis","volume":"197","author":"Chou","year":"2017","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.ucl.2026.03.005_bib2","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2026.03.005_bib3","unstructured":"Network NCC. Bladder Cancer. 2025."},{"issue":"5","key":"10.1016\/j.ucl.2026.03.005_bib4","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.euo.2022.05.005","article-title":"Intermediate-risk non-muscle-invasive bladder cancer: updated consensus definition and management recommendations from the International Bladder Cancer Group","volume":"5","author":"Tan","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.005_bib5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11912-022-01350-9","article-title":"Novel therapies for high-risk non-muscle invasive bladder cancer","volume":"25","author":"Al Hussein Al Awamlh","year":"2023","journal-title":"Curr Oncol Rep"},{"issue":"8","key":"10.1016\/j.ucl.2026.03.005_bib6","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1038\/s41591-025-03738-z","article-title":"Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial","volume":"31","author":"Shore","year":"2025","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.005_bib7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/JU.0000000000002186","article-title":"Primary chemoablation of low-grade intermediate-risk nonmuscle-invasive bladder cancer using UGN-102, a mitomycin-containing reverse thermal gel (optima II): a phase 2b, open-label, single-arm trial","volume":"207","author":"Chevli","year":"2022","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.005_bib8","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/JU.0000000000003645","article-title":"Treatment of low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102 \u00b1 transurethral resection of bladder tumor compared to transurethral resection of bladder tumor monotherapy: a randomized, controlled, phase 3 trial (ATLAS)","volume":"210","author":"Prasad","year":"2023","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.005_bib9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/JU.0000000000004296","article-title":"Primary chemoablation of recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102: a single-arm, open-label, phase 3 trial (ENVISION)","volume":"213","author":"Prasad","year":"2025","journal-title":"J Urol"},{"issue":"5_suppl","key":"10.1016\/j.ucl.2026.03.005_bib10","doi-asserted-by":"crossref","first-page":"TPS888","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS888","article-title":"ABLE-32: a randomized, controlled, phase 3b clinical trial of nadofaragene firadenovec-vncg versus observation in patients with intermediate-risk non\u2013muscle-invasive bladder cancer","volume":"43","author":"Shore","year":"2025","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.005_bib11","article-title":"MOONRISE-1: phase 3 study of TAR-210, an erdafitinib intravesical targeted releasing system, versus intravesical chemotherapy in patients with fgfr-altered intermediate-risk NON\u2013MUSCLE-INVASIVE bladder cancer","volume":"43","author":"Li GJ","year":"2025","journal-title":"Urol Oncol: Seminars and Original Investigations"},{"issue":"4_suppl","key":"10.1016\/j.ucl.2026.03.005_bib12","doi-asserted-by":"crossref","first-page":"TPS715","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS715","article-title":"PIVOT-006: a phase 3, randomized study of cretostimogene grenadenorepvec versus observation for the treatment of intermediate risk non-muscle invasive bladder cancer (IR-NMIBC) following transurethral resection of bladder tumor (TURBT)","volume":"42","author":"Svatek","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.005_bib13","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.eururo.2018.02.014","article-title":"Repeat transurethral resection in non-muscle-invasive bladder cancer: a systematic review","volume":"73","author":"Cumberbatch","year":"2018","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.005_bib14","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.eururo.2011.05.045","article-title":"Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review","volume":"60","author":"van den Bosch","year":"2011","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.005_bib15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BLC-150008","article-title":"Sequential intravesical gemcitabine and docetaxel for the salvage treatment of non-muscle invasive bladder cancer","volume":"1","author":"Steinberg","year":"2015","journal-title":"Bladder Cancer"},{"issue":"5","key":"10.1016\/j.ucl.2026.03.005_bib16","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/bju.14423","article-title":"Enhanced taxane uptake into bladder tissues following co-administration with either mitomycin C, doxorubicin or gemcitabine: association to exfoliation processes","volume":"122","author":"Pandey","year":"2018","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.005_bib17","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.euf.2021.07.018","article-title":"Sequential gemcitabine plus docetaxel is the standard second-line intravesical therapy for BCG-unresponsive non-muscle-invasive bladder cancer: pro","volume":"8","author":"Roumigui\u00e9","year":"2022","journal-title":"Eur Urol Focus"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.005_bib18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/JU.0000000000003977","article-title":"A phase 2 trial of intravesical gemcitabine and docetaxel in the treatment of bacillus Calmette-Gu\u00e9rin\u2012Na\u00efve nonmuscle-invasive urothelial carcinoma of the bladder","volume":"212","author":"Patel","year":"2024","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.005_bib19","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/JU.0000000000002740","article-title":"Sequential intravesical gemcitabine and docetaxel for bacillus calmette-gu\u00e9rin-na\u00efve high-risk nonmuscle-invasive bladder cancer","volume":"208","author":"McElree","year":"2022","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.005_bib20","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.0849","article-title":"Comparison of sequential intravesical gemcitabine and docetaxel vs bacillus calmette-Gu\u00e9rin for the treatment of patients with high-risk non-muscle-invasive bladder cancer","volume":"6","author":"McElree","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.005_bib21","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.euf.2023.06.006","article-title":"Background and update for ECOG-ACRIN EA8212: a randomized phase 3 trial of intravesical bacillus Calmette-Gu\u00e9rin (BCG) versus intravesical docetaxel and gemcitabine treatment in BCG-na\u00efve high-grade non-muscle-invasive bladder cancer (BRIDGE)","volume":"9","author":"Kates","year":"2023","journal-title":"Eur Urol Focus"},{"issue":"8","key":"10.1016\/j.ucl.2026.03.005_bib22","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3109\/02656736.2014.968640","article-title":"Local tumour hyperthermia as immunotherapy for metastatic cancer","volume":"30","author":"Toraya-Brown","year":"2014","journal-title":"Int J Hyperther"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.005_bib23","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000471701","article-title":"Combined intravesical chemotherapy with mitomycin C and local bladder microwave-induced hyperthermia as a preoperative therapy for superficial bladder tumors. A preliminary clinical study","volume":"20","author":"Rigatti","year":"1991","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.005_bib24","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00345-022-03928-1","article-title":"Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial","volume":"40","author":"Guerrero-Ramos","year":"2022","journal-title":"World J Urol"},{"issue":"8","key":"10.1016\/j.ucl.2026.03.005_bib25","doi-asserted-by":"crossref","first-page":"245.e19","DOI":"10.1016\/j.urolonc.2024.01.300","article-title":"HIVEC as an alternative option in non-muscle-invasive bladder cancer: experiences from a high-volume center","volume":"42","author":"Kastner","year":"2024","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.005_bib26","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/iju.12639","article-title":"Is thermochemotherapy with the synergo system a viable treatment option in patients with recurrent non-muscle-invasive bladder cancer?","volume":"22","author":"Kiss","year":"2015","journal-title":"Int J Urol"},{"issue":"7_suppl","key":"10.1016\/j.ucl.2026.03.005_bib27","doi-asserted-by":"crossref","first-page":"TPS500","DOI":"10.1200\/JCO.2019.37.7_suppl.TPS500","article-title":"A phase III, randomized, open-label, multicenter, global study of durvalumab and bacillus calmette-gu\u00e9rin (BCG) versus BCG alone in high-risk, BCG-na\u00efve non-muscle-invasive bladder cancer (NMIBC) patients (POTOMAC)","volume":"37","author":"Santis","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.005_bib29","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s11912-025-01657-3","article-title":"Current state of bladder preservation in high grade non-muscle invasive bladder cancer and localized muscle invasive bladder cancer","volume":"27","author":"Popli","year":"2025","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.005_bib30","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.urology.2013.10.030","article-title":"Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a food and Drug Administration and American Urological Association public workshop","volume":"83","author":"Jarow","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2026.03.005_bib31","unstructured":"Bacillus Calmette-Gu\u00e9rin-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biological Products for Treatment (2024)."},{"issue":"4","key":"10.1016\/j.ucl.2026.03.005_bib32","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrurol.2017.16","article-title":"BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG","volume":"14","author":"Kamat","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.ucl.2026.03.005_bib33","doi-asserted-by":"crossref","DOI":"10.1177\/1756287219839285","article-title":"Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: clinical trial evidence and experience","volume":"11","author":"Crist","year":"2019","journal-title":"Ther Adv Urol"},{"issue":"7","key":"10.1016\/j.ucl.2026.03.005_bib34","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.005_bib35","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S1470-2045(24)00178-5","article-title":"Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial","volume":"25","author":"Necchi","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.005_bib36","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.urology.2005.02.015","article-title":"Sustained intravesical interferon protein exposure is achieved using an adenoviral-mediated gene delivery system: a study in rats evaluating dosing regimens","volume":"66","author":"Connor","year":"2005","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.005_bib37","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.005_bib38","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/JU.0000000000004020","article-title":"Efficacy of intravesical nadofaragene firadenovec for patients with bacillus calmette-gu\u00e9rin-unresponsive nonmuscle-invasive bladder cancer: 5-year Follow-Up from a phase 3 trial","volume":"212","author":"Narayan","year":"2024","journal-title":"J Urol"},{"issue":"30","key":"10.1016\/j.ucl.2026.03.005_bib39","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1200\/JCO.2017.72.3064","article-title":"Intravesical rAd-IFN\u03b1\/Syn3 for patients with high-grade, bacillus calmette-guerin-refractory or relapsed non-muscle-invasive bladder cancer: a phase II randomized study","volume":"35","author":"Shore","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.005_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096705","article-title":"Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion","volume":"9","author":"Gomes-Giacoia","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.005_bib41","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200167","article-title":"IL-15 superagonist NAI in BCG-unresponsive non-muscle-invasive bladder cancer","volume":"2","author":"Chamie","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.ucl.2026.03.005_bib42","author":"Sayyid"},{"issue":"5","key":"10.1016\/j.ucl.2026.03.005_bib43","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.urolonc.2024.12.264","article-title":"Development of TAR-200: a novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer","volume":"43","author":"Daneshmand","year":"2025","journal-title":"Urol Oncol"},{"issue":"33","key":"10.1016\/j.ucl.2026.03.005_bib44","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1200\/JCO-25-01651","article-title":"TAR-200 for bacillus calmette-Gu\u00e9rin-unresponsive high-risk non-muscle-invasive bladder cancer: results from the phase iIb sunRISe-1 study","volume":"43","author":"Daneshmand","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.005_bib45","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1158\/1078-0432.CCR-05-1059","article-title":"CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer","volume":"12","author":"Ramesh","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"5S2","key":"10.1016\/j.ucl.2026.03.005_bib46","doi-asserted-by":"crossref","DOI":"10.1097\/01.JU.0001111604.90306.91.02","article-title":"Final results: BOND-003 cohort C- phase 3, single-arm study of intravesical CRETOSTIMOGENE GRENADENOREPVEC for high-risk BCG-unresponsive NON-muscle invasive bladder cancer with carcinoma in situ","volume":"213","author":"Tyson","year":"2025","journal-title":"J Urol"},{"issue":"5_suppl","key":"10.1016\/j.ucl.2026.03.005_bib47","doi-asserted-by":"crossref","first-page":"TPS902","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS902","article-title":"Expanded access program of cretostimogene grenadenorepvec in patients with non-muscle invasive bladder cancer unresponsive to bacillus Calmette-Guerin","volume":"43","author":"Psutka","year":"2025","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ucl.2026.03.005_bib48","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1200\/JCO.2024.42.16_suppl.4601","article-title":"Final results of CORE-001: a phase-2, single arm study of cretostimogene grenadenorepvec in combination with pembrolizumab in patients with BCG-unresponsive, non-muscle invasive bladder cancer with carcinoma in situ","volume":"42","author":"Li","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.005_bib49","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.euo.2025.05.019","article-title":"Real-world experience with a commercial circulating tumor DNA assay in non-muscle-invasive bladder cancer","volume":"8","author":"Wang","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"5_suppl","key":"10.1016\/j.ucl.2026.03.005_bib50","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1200\/JCO.2025.43.5_suppl.864","article-title":"Surveillance with plasma ctDNA in non-muscle invasive bladder cancer","volume":"43","author":"Kagathur","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T20:56:58Z","timestamp":1782507418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014326000315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0094014326000315"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2026.03.005","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging Intravesical Therapies for Non\u2013Muscle-Invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2026.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}